Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
Clinical trial NCT05156788 · UNKNOWN
Trial details
- NCT number
- NCT05156788
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-12
- Primary completion
- 2023-07-03
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.